<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Avicenna J Phytomed</journal-id><journal-id journal-id-type="iso-abbrev">Avicenna J Phytomed</journal-id><journal-id journal-id-type="publisher-id">IJP</journal-id><journal-title-group><journal-title>Avicenna Journal of Phytomedicine</journal-title></journal-title-group><issn pub-type="ppub">2228-7930</issn><issn pub-type="epub">2228-7949</issn><publisher><publisher-name>Mashhad University of Medical Sciences</publisher-name><publisher-loc>Mashhad, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27761427</article-id><article-id pub-id-type="pmc">5052420</article-id><article-id pub-id-type="publisher-id">AJP-6-567</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rahimi</surname><given-names>Hamid Reza</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mohammadpour</surname><given-names>Amir Hooshang</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dastani</surname><given-names>Mostafa</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Jaafari</surname><given-names>Mahmoud Reza</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Abnous</surname><given-names>Khalil</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ghayour Mobarhan</surname><given-names>Majid</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kazemi Oskuee</surname><given-names>Reza</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label><italic>Student Research Committee, Department of Modern Sciences &#x00026; Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</italic></aff><aff id="aff2"><label>2</label><italic>Pharmacetical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran</italic></aff><aff id="aff3"><label>3</label><italic>Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</italic></aff><aff id="aff4"><label>4</label><italic>Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran</italic></aff><aff id="aff5"><label>5</label><italic>Pharmaceutical Research Center, Department of Medicinal Chemistry, Mashhad University of Medical Sciences, Mashhad, Iran</italic></aff><aff id="aff6"><label>6</label><italic>Neurogenic Inflammation Research Center and Department of Medical Biotechnology, Mashhad University of Medical Sciences, Mashhad, Iran</italic></aff><author-notes><corresp id="cor1"><label>*</label>Corresponding Author: Tel: +985138002301, Fax: +985138002287, oskueekr@mums.ac.ir </corresp></author-notes><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2016</year></pub-date><volume>6</volume><issue>5</issue><fpage>567</fpage><lpage>577</lpage><history><date date-type="received"><day>28</day><month>5</month><year>2015</year></date><date date-type="rev-recd"><day>9</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>22</day><month>8</month><year>2015</year></date></history><permissions><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Objective:</title><p>Diabetes mellitus is defined as a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both or insulin resistance. Curcumin inhibits NF-&#x003ba;B signaling pathway. The aim of this study is evaluation of the effect of Nano-curcumin on HbA1C, fast blood glucose and lipid profile in diabetic patients.</p></sec><sec><title>Materials and Methods:</title><p>Seventy type-2 diabetic patients (fasting blood glucose (FBG) &#x02265; 126 mg/dL or 2-hr postprandial blood glucose &#x02265;200 mg/dl) randomly receivedeither Curcumin (as nano-micelle 80 mg/day) or placebo for 3 months in a double blind randomized clinical trial. Fasting blood glucose, HbA1C, and lipids profile were checked before and after the intervention. Data analyses, including parametric and nonparametric tests were done using the SPSS 11.5 software. A p value &#x0003c; 0.05 was regarded as statistically significant. (RCT registration code: IRCT2013081114330N1)</p></sec><sec><title>Results:</title><p>Mean age, BMI, FBG, total cholesterol (TC), triglyceride (TG), LDL, HDL, HbA1c , and sex and had no significant difference at the baseline between the groups. In Nano-curcumin group, a significant decrease was found in HbA1C, FBG, TG, and BMI comparing results of each subject before and after the treatment (p&#x0003c;0.05).</p><p>By comparing pre- and post-treatment values among the groups, HbA1c, eAG, LDL-C, and BMI variables showed significant differences (p&#x0003c;0.05). </p></sec><sec><title>Conclusion:</title><p> These findings suggest an HbA1c lowering effect for Nano-curcumin in type-2 diabetes; also, it is partially decrease in serum LDL-C and BMI.</p></sec></abstract><kwd-group><title>Key Words</title><kwd><italic>Curcumin</italic></kwd><kwd><italic>HbA1c</italic></kwd><kwd><italic>Fast blood glucose</italic></kwd><kwd><italic>Lipid profile</italic></kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Diabetes mellitus is defined as a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both or insulin resistance in skeletal muscle, liver and adipose tissues with a failure of b-cell compensation and a relative insulin deficiency (Association 2013<xref rid="B4" ref-type="bibr"> &#x025b6;</xref>; Pettitt et al. 2014<xref rid="B30" ref-type="bibr"> &#x025b6;</xref>). </p><p>The prevalence of diabetes globally was estimated to be 2.8% in 2000 and 4.4% in 2030 and is higher in men than women (Wild et al. 2004<xref rid="B43" ref-type="bibr"> &#x025b6;</xref>). There are 23.6 million children and adults in the United States, or 7.8% of the population in the USA who have diabetes. While an estimated number of 17.9 million have been diagnosed with diabetes, unfortunately, 5.7 million people (nearly one-quarter) are unaware that they have the disease. The Iranian diabetic population is estimated to be more than 1.5 million (Larejani and Zahedi 2001<xref rid="B19" ref-type="bibr"> &#x025b6;</xref>).</p><p>Free fatty acid metabolites could activate the serine kinase pathway. This signaling pathway influences insulin signaling and insulin receptor functions (<xref ref-type="fig" rid="F1">Figure 1</xref>)(Saini 2010<xref rid="B33" ref-type="bibr"> &#x025b6;</xref>).</p><p>Curcumin is a very active component which comes from the root of turmeric (in Farsi it is called Zardchobeh) (Chuengsamarn et al. 2014<xref rid="B6" ref-type="bibr"> &#x025b6;</xref>; Rahimi and Kazemi Oskuee 2014<xref rid="B32" ref-type="bibr"> &#x025b6;</xref>).</p><p>The chemical name of curcumin is diferuloylmethane or (1E, 6E)-1, 7-bis (4-hydroxy-3-methoxyphenyl)- 1, 6-heptadiene-3, 5-dione (Hatcher et al. 2008<xref rid="B13" ref-type="bibr"> &#x025b6;</xref>; Santel et al. 2008<xref rid="B35" ref-type="bibr"> &#x025b6;</xref>). Curcumin has antioxidative, anti-inflammatory, chemopreventive, and chemotherapeutic activity(Menon and Sudheer 2007<xref rid="B21" ref-type="bibr"> &#x025b6;</xref>; Sandur et al. 2007<xref rid="B34" ref-type="bibr"> &#x025b6;</xref>) with no significant side effects (Rahimi and Kazemi Oskuee 2014<xref rid="B32" ref-type="bibr"> &#x025b6;</xref>) it can also regulate multiple cell signaling pathways(Gupta et al. 2013<xref rid="B12" ref-type="bibr"> &#x025b6;</xref>). </p><p>Nuclear factor-&#x003ba;B (NF-&#x003ba;B) signaling pathway is one of the most important pathways in the cellular and molecular mechanisms of inflammation. In this cellular signaling pathway, cytokines and adhesion molecules are secreted. According to the molecular studies, curcumin inhibits NF-&#x003ba;B signaling pathway, which could regulate cytokines production and influence the immune response. Curcumin suppresses some genes expression, especially cytokines genes. Curcumin could down-regulate the expression of TNF &#x003b1;, IL-1, IL-6, IL-8, adhesion molecules (ICAM, VCAM), C-reactive protein (Rahimi and Kazemi Oskuee 2014<xref rid="B32" ref-type="bibr"> &#x025b6;</xref>; Rahimi et al. 2015<xref rid="B31" ref-type="bibr"> &#x025b6;</xref>).</p><p>Curcumin can have a therapeutic effect onall human chronic diseases such as asthma, bronchitis, inflammatory bowel disease, rheumatoid arthritis, coronary artery disease, atherosclerosis plaque stabilizing, diabetes mellitus, obesity, fatty liver, metabolic syndrome, depression, cancer, and allergy (Aggarwal and Harikumar 2009<xref rid="B1" ref-type="bibr"> &#x025b6;</xref>).</p><p>Curcumin administration in the pre-diabetic population decreased the number of pre-diabetic individuals who eventually developed type-2 diabetes mellitus properly (T2DM) (Chuengsamarn et al. 2012<xref rid="B6" ref-type="bibr"> &#x025b6;</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Over-nutrition could influence on cytokine production by macrophages, liver, and adipose tissue. These cytokines produce insulin resistance and fatty liver(JNK: Jun N-terminal kinase, NF-&#x00138;B: nuclear factor kappa-light-chain-enhancer of activated B cells) (Gao and Bataller 2011</p></caption><graphic xlink:href="AJP-6-567-g001"/></fig><p>
<bold>Nano-curcumin</bold>
</p><p>Nano-Curcumin is a registered curcumin product (SinaCurcumin&#x000ae;) for oral use which has been developed in Nanotechnology Research Center of Mashhad University of Medical Sciences, Mashhad, Iran and marketed by Exir Nano Sina Company in Tehran-Iran (IRC:1228225765). Each soft gel of Nano-curcumin contains 80 mg of curcumin in the form of nano-micelle. The oral absorption of curcumin is very poor due to its hydrophobic nature. However, Nano-curcumin has a significantly higher bioavailability after oral use compared to the simple powder of curcumin (Rahimi, Jaafari et al. 2015<xref rid="B31" ref-type="bibr"> &#x025b6;</xref>). </p><p>In the present study, we examined the effect of Nano micelle curcumin on HbA1C, fasting blood glucose and lipid profile in diabetic subjectsin comparison with the placebo group.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><p>
<bold>Study design and participants</bold>
</p><p>A double blind randomized placebo-control add-on clinical trial (registration code: IRCT2013081114330N1) was set up in Mashhad University of medical Sciences.</p><p>Seventy type-2 diabetic patients (fasting blood glucose (FBG) &#x02265; 126 mg/dl or 2-hr postprandial blood glucose &#x02265;200 mg/dl) were randomly assigned to Nano-curcumin (as nano-micelle 80 mg/day) or placebo for 3 months in a double blind randomized clinical trial. According to the ethical issues all other necessary medications were given to subjects, so, this study is an add-on therapy. All patients were observed by the same researcher during this study. </p><p>
<bold>Randomization procedures</bold>
</p><p>After screening process, diet and lifestyle training were done face-to-face. All subjects were randomly assigned to either the Nano-curcumin (as nano-micelle 80 mg/day) or placebo-treated group (control condition) using a fixed randomization scheme based on random numbers provided by a computer software. The subjects were informed that two methods of interventions were being evaluated (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Flow chart of participants</p></caption><graphic xlink:href="AJP-6-567-g002"/></fig><p>
<bold>Inclusion criteria </bold>
</p><p>Subjectswho were included in the present study were:</p><p>Suspected CAD by the selected cardiologist, Male/ Female older than 18 years of age, and they understood the study procedures and agreed to participate.</p><p>
<bold>Exclusion criteria for case and control group</bold>
</p><p>Pregnant and breast-feeding patients were excluded from the present study. In addition, based on the case and control subject&#x02019;s past medical history taken by the cardiologist, those who reported any of the following diseases were also excluded from the study:Rheumatic disease, chronic liver disease, renal disease, any type of cancer, infectious disease in the last 3 months, people with any surgical procedures in the preceding 3 months, subjects who had a history of angioplasty or coronary by-pass graft surgery, subjects who had a traumatic or major immunologic disease, subjects who were usingsteroids, penicillin, oral contraceptive or hormone replacement therapy. Also,subjects with any inflammatory disease such as inflammatory bowel disease, psoriasis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, autoimmune thyroiditis were excluded from the study (de Freitas, Pinheiro, Miranda, Thiers, de Barros Vieira, Pernambuco and Pe 2001; Kazemi-Bajestani, Ghayour-Mobarhan, Ebrahimi, Moohebati, Esmaeili and Ferns 2008; MJ Zibaee Nezhad, P Ghanbari, B Shahryari and Aghasadeghi 2009).</p><p>
<bold>Collecting subjects' data</bold>
</p><p>A general questionnaire was used to obtain information including demographic data and anthropometric parameters. According to the standard procedures, blood pressure was measured using a mercury sphygmomanometer and periodical validity and reliability of the instrument was checked. Height was measured using a wall-mounted stadiometer. Weight was measured using electronic scales while the subject was wearing light clothing without shoes.</p><p>
<bold>Laboratory tests</bold>
</p><p>Blood samples were obtained in the early morning after an overnight fasting. Fasting blood samples (10 ml) were collected into plain Vacutainer&#x02122; tubes, for lipid profile, HbA1C.For measurement of fasting blood glucose, blood was taken into Vacutainer&#x02122; tubes containing fluoride-oxalate (Kazemi-Bajestani, Ghayour-Mobarhan, Ebrahimi, Moohebati, Esmaeili and Ferns 2007<xref rid="B18" ref-type="bibr"> &#x025b6;</xref>).</p><p>Blood samples were centrifuged for plasma separation (4000 RPM, 4 min). Total cholesterol, low density lipoprotein cholesterol, high density lipoprotein, cholesterol, and glucose were measured using routine techniques by a Cobas auto-analyser system (ABX Diagnostics, Montpellier, France) (Kazemi-Bajestani et al. 2007<xref rid="B18" ref-type="bibr"> &#x025b6;</xref>).</p><p>The results of the fasting blood sugar (FBS) &#x0003c; 110 mg/dl were interpreted using the American Diabetic Association criteria: normal values between 110 and 126 mg/dl, and those &#x0003e; 126 mg/dl are considered as impaired fasting glucose (IFG) and DM, respectivelyall(Pekkanen e al. 1999<xref rid="B29" ref-type="bibr"> &#x025b6;</xref>; Kazemi-Bajestani et al. 2007<xref rid="B18" ref-type="bibr"> &#x025b6;</xref>).</p><p>
<bold>Ethical issues</bold>
</p><p>All participants were provided with information about the study both verbally and by written informed consent. All those who hadthe exclusion criteria including those who preferred not to attend at any stage were withdrawn from the study. Each patient gave informed written consent to participate in the study, which was approved by the Ethics Committee of Mashhad University of Medical Sciences. This form was agreed and completed by all subjects. The investigation conforms to the principles outlined in the Declaration of Helsinki.</p><p>
<bold>Sample Size</bold>
</p><p>Sample size was calculated using frequency data of previous studies (Chuengsamarn, Rattanamongkolgul, Phonrat, Tungtrongchitr and Jirawatnotai 2014<xref rid="B7" ref-type="bibr"> &#x025b6;</xref>; Ghorbani, Hekmatdoost and Mirmiran 2014<xref rid="B11" ref-type="bibr"> &#x025b6;</xref>; Nauck, Meininger, Sheng, Terranella and Stein 2007<xref rid="B26" ref-type="bibr"> &#x025b6;</xref>) with an 80% power, 5% level of significance, and a SD of 35.3. We enrolled at least 35 subjects in each treatment group.</p><p>
<bold>Statistical analysis</bold>
</p><p>All statistical analyses were performed using SPSS for (of) Windows&#x02122;, version 11.5 software package (SPSS Inc., Chicago, IL, USA). At first, quantitative data were assessed using Kolmogorov-Smirnov tests to check normality. Data were expressed as Mean&#x000a0;&#x000b1;&#x000a0;SD for parameters with a normal distribution or median and interquartile range for non-normally distributed data. Group comparisons were performed using sample T-Test or Mann-Whitney U test (in case of non-normally distributed data). A two-sided p value&#x000a0;&#x0003c;&#x000a0;0.05 was considered statistically significant.</p></sec><sec sec-type="results"><title>Results</title><p>Baseline demographic and biochemical serum parameters are matched (such as age, sex, body mass index, smoking habit, hypertension, fasting blood glucose, HbA1c, estimated Average Glucose (eAG), total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, and triglyceride) theyshowed) no statistically significant difference between the groups(<xref ref-type="table" rid="T1">Tables 1</xref> and <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the study population stratified by groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="2">
<bold>Variables</bold>
</th><th align="center" colspan="2" rowspan="1">
<bold>Groups</bold>
<hr/>
</th><th align="left" rowspan="2" colspan="1">
<bold>p value</bold>
</th></tr><tr><th align="left" rowspan="1" colspan="1">
<bold>Nano-curcumin</bold>
<break/>
<bold>N=35</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Placebo</bold>
<break/>
<bold>N=35</bold>
</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">
<bold>Age(y)</bold>
</td><td align="left" rowspan="1" colspan="1">56.34 &#x000b1; 11.17</td><td align="left" rowspan="1" colspan="1">60.95 &#x000b1; 10.77</td><td align="left" rowspan="1" colspan="1">0.132</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Sex</bold>
</td><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">17(48.5)</td><td align="left" rowspan="1" colspan="1">14(40)</td><td align="left" rowspan="2" colspan="1">0.518</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">18(51.5)</td><td align="left" rowspan="1" colspan="1">21(60)</td></tr><tr><td align="left" rowspan="3" colspan="1">
<bold>BMI (kg/m</bold>
<sup>2</sup>
<bold>)</bold>
</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="left" rowspan="1" colspan="1">3(8.5)</td><td align="left" rowspan="1" colspan="1">5(14.3)</td><td align="left" rowspan="3" colspan="1">&#x0003e;0.999</td></tr><tr><td align="left" rowspan="1" colspan="1">Overweight</td><td align="left" rowspan="1" colspan="1">26(74.2)</td><td align="left" rowspan="1" colspan="1">25(71.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Obesity</td><td align="left" rowspan="1" colspan="1">6(17.3)</td><td align="left" rowspan="1" colspan="1">5(14.3)</td></tr><tr><td align="left" rowspan="3" colspan="1">
<bold>Smoking habit</bold>
</td><td align="left" rowspan="1" colspan="1">Current</td><td align="left" rowspan="1" colspan="1">4(11.5)</td><td align="left" rowspan="1" colspan="1">3(8.6)</td><td align="left" rowspan="3" colspan="1">0.949</td></tr><tr><td align="left" rowspan="1" colspan="1">Former</td><td align="left" rowspan="1" colspan="1">10(28.5)</td><td align="left" rowspan="1" colspan="1">9(25.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Never</td><td align="left" rowspan="1" colspan="1">21(60)</td><td align="left" rowspan="1" colspan="1">23(65.7)</td></tr><tr><td align="left" rowspan="2" colspan="1">
<bold>Hypertension, No.</bold> (<bold>%)</bold></td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">18(51.5)</td><td align="left" rowspan="1" colspan="1">21(60)</td><td align="left" rowspan="2" colspan="1">0.518</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">17(48.5)</td><td align="left" rowspan="1" colspan="1">14(40)</td></tr></tbody></table><table-wrap-foot><p>BMI: Body Mass Index. Data are shown as Mean&#x000b1;SD or No.(%).</p></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Serum biochemical parameters and some other characteristics of study groups after clinical trial</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="3">
<bold>Variables</bold>
</th><th align="center" colspan="2" rowspan="1">
<bold>Before</bold>
<hr/>
</th><th align="center" colspan="2" rowspan="1">
<bold>After</bold>
<hr/>
</th><th align="center" colspan="4" rowspan="2">
<bold>p value</bold>
</th></tr><tr><th align="left" colspan="2" rowspan="1">
<bold>Groups</bold>
</th><th align="left" colspan="2" rowspan="1">
<bold>Groups</bold>
</th></tr><tr><th align="left" rowspan="1" colspan="1">
<bold>Nano-curcumin</bold>
<break/>
<bold>N=35</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Placebo</bold>
<break/>
<bold>N=35</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Nano-curcumin</bold>
<break/>
<bold>N=35</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Placebo</bold>
<break/>
<bold>N=35</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>P1</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>P2</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>P3</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>P4</bold>
</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">
<bold>FBG(mg/dl)</bold>
</td><td align="left" rowspan="1" colspan="1">135.5&#x000b1;51.33</td><td align="left" rowspan="1" colspan="1">148.30&#x000b1;76.41</td><td align="left" rowspan="1" colspan="1">120.29&#x000b1;38.01</td><td align="left" rowspan="1" colspan="1">176.0&#x000b1;61.56</td><td align="left" rowspan="1" colspan="1">0.154</td><td align="left" rowspan="1" colspan="1">0.004</td><td align="left" rowspan="1" colspan="1">0.049</td><td align="left" rowspan="1" colspan="1">0.204</td></tr><tr><td align="left" colspan="2" rowspan="1">
<bold>HbA1c (%)</bold>
</td><td align="left" rowspan="1" colspan="1">7.59&#x000b1;1.74</td><td align="left" rowspan="1" colspan="1">7.49&#x000b1;1.75</td><td align="left" rowspan="1" colspan="1">7.31&#x000b1;1.54</td><td align="left" rowspan="1" colspan="1">9.00&#x000b1;2.33</td><td align="left" rowspan="1" colspan="1">0.838</td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">0.521</td></tr><tr><td align="left" colspan="2" rowspan="1">
<bold>eAG</bold>
</td><td align="left" rowspan="1" colspan="1">171.2&#x000b1;50.0</td><td align="left" rowspan="1" colspan="1">168.4&#x000b1;50.35</td><td align="left" rowspan="1" colspan="1">167.00&#x000b1;51.0</td><td align="left" rowspan="1" colspan="1">211.6&#x000b1;66.9</td><td align="left" rowspan="1" colspan="1">0.838</td><td align="left" rowspan="1" colspan="1">0.050</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">0.521</td></tr><tr><td align="left" colspan="2" rowspan="1">
<bold>TC (mg/dl)</bold>
</td><td align="left" rowspan="1" colspan="1">163.4&#x000b1;33.94</td><td align="left" rowspan="1" colspan="1">162.4&#x000b1;38.59</td><td align="left" rowspan="1" colspan="1">158.62&#x000b1;44.06</td><td align="left" rowspan="1" colspan="1">149.00&#x000b1;24.62</td><td align="left" rowspan="1" colspan="1">&#x0003e;0.999</td><td align="left" rowspan="1" colspan="1">0.542</td><td align="left" rowspan="1" colspan="1">0.018</td><td align="left" rowspan="1" colspan="1">0.245</td></tr><tr><td align="left" colspan="2" rowspan="1">
<bold>LDL-C (mg/dl)</bold>
</td><td align="left" rowspan="1" colspan="1">96.57&#x000b1;33.94</td><td align="left" rowspan="1" colspan="1">99.78&#x000b1;30.33</td><td align="left" rowspan="1" colspan="1">91.04&#x000b1;28.72</td><td align="left" rowspan="1" colspan="1">84.00&#x000b1;12.59</td><td align="left" rowspan="1" colspan="1">0.723</td><td align="left" rowspan="1" colspan="1">0.486</td><td align="left" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">0.316</td></tr><tr><td align="left" colspan="2" rowspan="1">
<bold>HDL-C (mg/dl)</bold>
</td><td align="left" rowspan="1" colspan="1">54.30&#x000b1;14.02</td><td align="left" rowspan="1" colspan="1">60.35&#x000b1;15.96</td><td align="left" rowspan="1" colspan="1">60.95&#x000b1;15.68</td><td align="left" rowspan="1" colspan="1">55.00&#x000b1;11.09</td><td align="left" rowspan="1" colspan="1">0.064</td><td align="left" rowspan="1" colspan="1">0.734</td><td align="left" rowspan="1" colspan="1">0.014</td><td align="left" rowspan="1" colspan="1">0.323</td></tr><tr><td align="left" colspan="2" rowspan="1">
<bold>TG (mg/dl)(median(IQR))</bold>
</td><td align="left" rowspan="1" colspan="1">109(94.75)</td><td align="left" rowspan="1" colspan="1">142(97.50)</td><td align="left" rowspan="1" colspan="1">131(60.27)</td><td align="left" rowspan="1" colspan="1">113(58.0)</td><td align="left" rowspan="1" colspan="1">0.475</td><td align="left" rowspan="1" colspan="1">0.050</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">0.387</td></tr><tr><td align="left" colspan="2" rowspan="1">
<bold>BMI(kg/m</bold>
<sup>2</sup>
<bold>)</bold>
</td><td align="left" rowspan="1" colspan="1">26.92&#x000b1;2.71</td><td align="left" rowspan="1" colspan="1">27.27&#x000b1;3.59</td><td align="left" rowspan="1" colspan="1">25.57&#x000b1;2.71</td><td align="left" rowspan="1" colspan="1">27.50&#x000b1;3.38</td><td align="left" rowspan="1" colspan="1">0.667</td><td align="left" rowspan="1" colspan="1">0.019</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">0.452</td></tr><tr><td align="left" rowspan="3" colspan="1">
<bold>BMI (kg/m</bold>
<sup>2</sup>
<bold>)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Normal</bold>
</td><td align="left" rowspan="1" colspan="1">3(8.5)</td><td align="left" rowspan="1" colspan="1">5(14.3)</td><td align="left" rowspan="1" colspan="1">12(34)</td><td align="left" rowspan="1" colspan="1">5(14.3)</td><td align="left" rowspan="3" colspan="1">&#x0003e;0.999</td><td align="left" rowspan="3" colspan="1">0.042</td><td align="left" rowspan="3" colspan="1">0.032</td><td align="left" rowspan="3" colspan="1">0.705</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Overweight</bold>
</td><td align="left" rowspan="1" colspan="1">26(74.2)</td><td align="left" rowspan="1" colspan="1">25(71.4)</td><td align="left" rowspan="1" colspan="1">22(63)</td><td align="left" rowspan="1" colspan="1">25(71.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Obesity</bold>
</td><td align="left" rowspan="1" colspan="1">6(17.3)</td><td align="left" rowspan="1" colspan="1">5(14.3)</td><td align="left" rowspan="1" colspan="1">1(3)</td><td align="left" rowspan="1" colspan="1">5(14.3)</td></tr></tbody></table><table-wrap-foot><p>BMI: Body Mass Index, FBG: Fasting blood glucose, TC: total cholesterol, HDL-C: High density lipoprotein- cholesterol, LDL-C: Low density lipoprotein- cholesterol, TG: triglyceride, IQR: Interquartile Range. Data are shown as Mean&#x000b1;SD or median (IQR) or No.(%).eAG: estimated Average Glucose =(28.7<inline-formula><mml:math id="M1"><mml:mo>&#x000d7;</mml:mo></mml:math></inline-formula>HbA1CHbA1c)-46.7. </p><p>P1 is the p value of comparing Nano-curcumin with Placebo before intervention. </p><p>P2 is the p value of comparing Nano-curcumin with Placebo after intervention.</p><p>P3 is the p value of comparing data in Nano-curcumin group between before and after using pair T test.</p><p>P4 is the p value of comparing data in Placebo group between before and after using pair T test.</p></table-wrap-foot></table-wrap><p>In <xref ref-type="table" rid="T2">Table 2</xref>, body mass index, fasting blood glucose, HbA1C, estimated Average Glucose (eAG), total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, and triglyceride were compared between the 2 groups after the intervention.Curcumin improved FBG, HbA1c, BMI, and eAG, but had no effect on LDL, HDL, TG and TC(<xref ref-type="table" rid="T2">Table 2</xref>).</p><p>Pairedt test was used to compare FBG, HbA1c, eAG, TG, TC, LDL-C, and HDL-C for each subject before and after the intervention. Regarding all above-mentioned variables, in curcumin-treated group, statistically significant differences were found before and after the intervention (p=0.049, p&#x0003c;0.001, p&#x0003c;0.001, p=0.018, p=0.01, p=0.014, and p&#x0003c;0.001, respectively). However, in placebo group, there were no differences between the results of FBG, HbA1c, eAG, TG, TC, LDL-C, and HDL-C in baseline and endpoint results (p=0.204, p=0.521, p=0.521, p=0.254, p=0.316, p=0.323, and p=0.387)(<xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="table" rid="T3">3</xref> and <xref ref-type="fig" rid="F3">Figures 3</xref> and <xref ref-type="fig" rid="F4">4</xref>).</p><p>Determination of longitudinal changes of FBG, HbA1c, eAG, TG, TC, LDL-C, HDL-C, and BMI before and after of this is shown in <xref ref-type="table" rid="T3">Table 3</xref>. Significant difference was found between groups in HbA1c, eAG, LDL-C, and BMI (p&#x0003c;0.05) (<xref ref-type="table" rid="T3">Table 3</xref>).</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Determination (delta, &#x00394;) of changes in some variables before and after the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">
<bold>Variables</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Nano-curcumin</bold>
<break/>
<bold>N=35</bold>
<break/>
<bold>(&#x00394;=after- before)</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>Placebo</bold>
<break/>
<bold>N=35</bold>
<break/>
<bold>(&#x00394;=after- before)</bold>
</th><th align="left" rowspan="1" colspan="1">
<bold>p value</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x00394;FBG</bold>
</td><td align="left" rowspan="1" colspan="1">-17.12&#x000b1;40.38</td><td align="left" rowspan="1" colspan="1">-24.88&#x000b1;53.94</td><td align="left" rowspan="1" colspan="1">0.657</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x00394;HbA1c</bold>
</td><td align="left" rowspan="1" colspan="1">-0.91&#x000b1;1.11</td><td align="left" rowspan="1" colspan="1">0.33&#x000b1;1.48</td><td align="left" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x00394;eAG</bold>
</td><td align="left" rowspan="1" colspan="1">-21.88&#x000b1;25.42</td><td align="left" rowspan="1" colspan="1">9.56&#x000b1;42.71</td><td align="left" rowspan="1" colspan="1">0.015</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x00394;TC</bold>
</td><td align="left" rowspan="1" colspan="1">-15.45&#x000b1;44.75</td><td align="left" rowspan="1" colspan="1">-13.11&#x000b1;36.74</td><td align="left" rowspan="1" colspan="1">0.889</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x00394;LDL-C</bold>
</td><td align="left" rowspan="1" colspan="1">-16.41&#x000b1;30.93</td><td align="left" rowspan="1" colspan="1">-8.95&#x000b1;25.51</td><td align="left" rowspan="1" colspan="1">0.046</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x00394;HDL-C</bold>
</td><td align="left" rowspan="1" colspan="1">1.83&#x000b1;13.11</td><td align="left" rowspan="1" colspan="1">2.11&#x000b1;6.91</td><td align="left" rowspan="1" colspan="1">0.952</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x00394;TG</bold>
</td><td align="left" rowspan="1" colspan="1">-6.7&#x000b1;67.52</td><td align="left" rowspan="1" colspan="1">-15.33&#x000b1;37.39</td><td align="left" rowspan="1" colspan="1">0.772</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>&#x00394;BMI</bold>
</td><td align="left" rowspan="1" colspan="1">-1.34&#x000b1;1.88</td><td align="left" rowspan="1" colspan="1">0.22&#x000b1;1.31</td><td align="left" rowspan="1" colspan="1">0.001</td></tr></tbody></table><table-wrap-foot><p>&#x00394;=after- before for ech value, BMI: Body Mass Index, FBG: Fasting blood glucose, TC: total cholesterol, HDL-C: High density lipoprotein- cholesterol, LDL-C: Low density lipoprotein- cholesterol, TG: triglyceride, IQR: Interquartile Range.eAG: estimated Average Glucose =(28.7<inline-formula><mml:math id="M2"><mml:mo>&#x000d7;</mml:mo></mml:math></inline-formula>HbA1CHbA1c)-46.7</p></table-wrap-foot></table-wrap><fig id="F3" position="float"><label>Figure 3</label><caption><p>Fasting blood glucose and estimated Average Glucose, before and after the intervention in both groups. *p&#x0003c;0.05, **p&#x0003c;0.01: statistically significant difference between before and after the intervention using pair t test</p></caption><graphic xlink:href="AJP-6-567-g003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p>Total cholesterol, High-density lipoprotein-cholesterol, Low-density lipoprotein- cholesterol before and after intervention in both groups. *Statistically significant difference between before and after the intervention (P&#x0003c;0.05) using pair and independent T test</p></caption><graphic xlink:href="AJP-6-567-g004"/></fig><p>As noted before (<xref ref-type="fig" rid="F2">Figure 2</xref>), 10 patients in both groups did not complete the procedure of this study, due to long distance to the institution, their health insurance and crowdedness of Ghaem Academic hospital, Mashhad, Iran.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>A large number of studies has been conducted on the physicochemical traits and pharmacological effects of curcumin on different diseases like cardiovascular diseases, diabetes, cancer, rheumatoid arthritis, Alzheimer&#x02019;s, inflammatory bowel disease (IBD), or even wound healing, due to its minor toxicity (Soni and Kuttan 1992<xref rid="B39" ref-type="bibr"> &#x025b6;</xref>; Garodia et al. 2007<xref rid="B10" ref-type="bibr"> &#x025b6;</xref>; Liu et al. 2013<xref rid="B20" ref-type="bibr"> &#x025b6;</xref>). The use of curcumin for treatment of these conditions has revealed that curcumin modulates several transcription factors, kinases, growth factors, cytokines, and some other enzymes (Kakarala et al. 2010<xref rid="B16" ref-type="bibr"> &#x025b6;</xref>; Thamake et al. 2011<xref rid="B40" ref-type="bibr"> &#x025b6;</xref>; Venkatesha et al. 2011<xref rid="B41" ref-type="bibr"> &#x025b6;</xref>). Other studies showed that curcumin has anti-diabetic activities (Yeh et al. 2003<xref rid="B44" ref-type="bibr"> &#x025b6;</xref>; Hsu and Cheng 2007<xref rid="B15" ref-type="bibr"> &#x025b6;</xref>).</p><p>Insulin resistance (IR) is the backbone of T2DM (Na et al. 2011<xref rid="B25" ref-type="bibr"> &#x025b6;</xref>); It was reported that curcumin could break IR (Neerati et al. 2014). Also, curcumin could increase the activation of PPAR-&#x003b3; (Nishiyama et al. 2005<xref rid="B28" ref-type="bibr"> &#x025b6;</xref>). PPAR-&#x003b3; activity suppresses low-density lipoprotein (LDL) receptor and it could be used as a treatment of hypercholesterolemia (Kang and Chen 2009<xref rid="B17" ref-type="bibr"> &#x025b6;</xref>).</p><p>Curcumin may prevent diabetes mellitus microvascular and macrovascular complications (Sharma et al. 2006<xref rid="B36" ref-type="bibr"> &#x025b6;</xref>; Muthenna et al. 2009<xref rid="B24" ref-type="bibr"> &#x025b6;</xref>). </p><p>A great problem that should be considered is that several studies on chemical structure of curcumin (a polyphenolic compound) have shown that this substance has a poor bioavailability (Chainani-Wu 2003<xref rid="B5" ref-type="bibr"> &#x025b6;</xref>; Anand et al. 2007<xref rid="B3" ref-type="bibr"> &#x025b6;</xref>; Hatcher, Planalp et al. 2008<xref rid="B13" ref-type="bibr"> &#x025b6;</xref>). In addition, it has a low absorption, fast metabolism, and fast systemic elimination (Anand, Kunnumakkara et al. 2007<xref rid="B3" ref-type="bibr"> &#x025b6;</xref>).</p><p>To overcome curcumin's poor bioavailability, nano-micelle containing curcumin which is a registered curcumin product (SinaCurcumin&#x000ae;) was prepared for oral use. These nano-micelles are prepared from GRAS (generally recognized as safe) pharmaceutical excipients and C3-complex form of curcumin. The percentage of encapsulation of curcumin in this nano-micelle is close to 100% and their sizes are around 10 nm. Nano-curcumin has a significantly higher bioavailability after oral use as compared to simple powder of curcumin due to the following reasons:An intact layer of water is on the surface of intestinal epithelial cells (unstirred water layer), so any medication should pass this barrier (Smithson et al. 1981<xref rid="B38" ref-type="bibr"> &#x025b6;</xref>), this is a confronting barrier for lipophilic molecules such as curcumin. Bile salts largely facilitates absorption and soluble substances such as lipophilic vitamins, lipids, fatty acids and cholesterol(Howles 2010<xref rid="B14" ref-type="bibr"> &#x025b6;</xref>) and also the same happens for curcumin as nano-micelles. After oral administration, soft gel of Nano-curcumin opens in the stomach in less than 15 minutes and will be diffused to the small intestine; this product has a higher bioavailability than other similar products(Rahimi and Kazemi Oskuee 2014<xref rid="B32" ref-type="bibr"> &#x025b6;</xref>). </p><p>In this clinical trial, we found that Nano-curcumin reduces FBG and HbA1c during 3 months of therapy; it could also significantly reduce eAG and lipid profile parameters. Obesity is one of the most important factors in IR and T2DM development (Weisberg et al. 2008<xref rid="B42" ref-type="bibr"> &#x025b6;</xref>). In this research, we found that curcumin has a good influence on BMI in diabetic patients. </p><p>Also, it was found that one-month oral administration of curcumin (1 gram/day) could reduce triglycerides concentrations in obese subjects (Mohammadi et al. 2013<xref rid="B23" ref-type="bibr"> &#x025b6;</xref>).</p><p>According to the Framingham Heart Study, level of HbA1c has a great association with cardiovascular disease and T2DM (Singer et al. 1992<xref rid="B37" ref-type="bibr"> &#x025b6;</xref>).</p><p>Moreover, it was shown that low dose of oral curcumin could reduce LDL-C and TC (Alwi et al. 2008<xref rid="B2" ref-type="bibr"> &#x025b6;</xref>). We compared serum levels of TC, TG, LDL-C, and HDL-C, before and after the treatment and significant differences were found for each subject in Nano-curcumin group.</p></sec></body><back><ack><title>Acknowledgment</title><p>Mashhad University of Medical Science Research Council supported this research. Data presented here was from a PhD thesis. In addition, authors would like to thank Dar Al-Shifa Imam Reza Medical laboratory staffs, Mrs. Sareh Ejlali for her kind cooperation, and Dr Taghiabadi drugstore.</p></ack><sec><title>Note</title><p>
<italic>Please cite this paper as</italic>
</p><p>Rahimi HR, Mohammadpour AH, Dastani M, Jafari MR, Abnous K, Mobarhan MG, Kazemi Oskuee R.The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial.Avicenna J Phytomed, 2016; 6 (5): 567-577.</p></sec><sec><title>Conflict of interest</title><p>The authors have no conflict of interests to declare.</p></sec><ref-list><title>References</title><ref id="B1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>BB</given-names></name><name><surname>Harikumar</surname><given-names>KB</given-names></name></person-group><article-title>Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases</article-title><source> Int J Biochem Cell Biol</source><year>2009</year><volume>41</volume><fpage>40</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">18662800</pub-id></element-citation></ref><ref id="B2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alwi</surname><given-names>I</given-names></name><name><surname>Santoso</surname><given-names>T</given-names></name><name><surname>Suyono</surname><given-names>S</given-names></name><name><surname>Sutrisna</surname><given-names>B</given-names></name><name><surname>Suyatna</surname><given-names>FD</given-names></name><name><surname>Kresno</surname><given-names>SB</given-names></name><name><surname>Ernie</surname><given-names>S</given-names></name></person-group><article-title>The effect of curcumin on lipid level in patients with acute coronary syndrome</article-title><source> Acta Med Indones</source><year>2008</year><volume>40</volume><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">19151449</pub-id></element-citation></ref><ref id="B3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>P</given-names></name><name><surname>Kunnumakkara</surname><given-names>AB</given-names></name><name><surname>Newman</surname><given-names>RA</given-names></name><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group><article-title>Bioavailability of curcumin: problems and promises</article-title><source> Mol Pharm</source><year>2007</year><volume>46</volume><fpage>807</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">17999464</pub-id></element-citation></ref><ref id="B4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Association</surname><given-names>AD</given-names></name></person-group><article-title>Diagnosis and classification of diabetes mellitus</article-title><source> Diabetes care</source><year>2013</year><volume>36</volume><fpage>S67</fpage><lpage>S74</lpage><pub-id pub-id-type="pmid">23264425</pub-id></element-citation></ref><ref id="B5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chainani-WuN</surname><given-names/></name></person-group><article-title>Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa)</article-title><source> J Altern Complement Med</source><year>2003</year><volume>91</volume><fpage>161</fpage><lpage>168</lpage></element-citation></ref><ref id="B6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chuengsamarn</surname><given-names>S</given-names></name><name><surname>Rattanamongkolgul</surname><given-names>S</given-names></name><name><surname>Luechapudiporn</surname><given-names>R</given-names></name><name><surname>Phisalaphong</surname><given-names>C</given-names></name><name><surname>Jirawatnotai</surname><given-names>S</given-names></name></person-group><article-title>Curcumin extract for prevention of type 2 diabetes</article-title><source> Diabetes Care</source><year>2012</year><volume>35</volume><fpage>2121</fpage><lpage>2127</lpage><pub-id pub-id-type="pmid">22773702</pub-id></element-citation></ref><ref id="B7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chuengsamarn</surname><given-names>S</given-names></name><name><surname>Rattanamongkolgul</surname><given-names>S</given-names></name><name><surname>Phonrat</surname><given-names>B</given-names></name><name><surname>Tungtrongchitr</surname><given-names>R</given-names></name><name><surname>Jirawatnotai</surname><given-names>S</given-names></name></person-group><article-title>Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial</article-title><source> J Nutr Biochem</source><year>2014</year><volume>25</volume><fpage>144</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">24445038</pub-id></element-citation></ref><ref id="B8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freitas</surname><given-names>AC</given-names></name><name><surname>Pinheiro</surname><given-names>AL</given-names></name><name><surname>Miranda</surname><given-names>P</given-names></name><name><surname>Thiers</surname><given-names>FA</given-names></name><name><surname>Vieira</surname><given-names>AL</given-names></name></person-group><article-title>Assessment of anti-inflammatory effect of 830nm laser light using C-reactive protein levels</article-title><source> Braz Dent J</source><year>2001</year><volume>12</volume><fpage>187</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">11696916</pub-id></element-citation></ref><ref id="B9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Bataller</surname><given-names>R</given-names></name></person-group><article-title>Alcoholic liver disease: pathogenesis and new therapeutic targets</article-title><source> Gastroenterology</source><year>2011</year><volume>141</volume><fpage>1572</fpage><lpage>1585</lpage><pub-id pub-id-type="pmid">21920463</pub-id></element-citation></ref><ref id="B10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garodia</surname><given-names>P</given-names></name><name><surname>Ichikawa</surname><given-names>H</given-names></name><name><surname>Malani</surname><given-names>N</given-names></name><name><surname>Sethi</surname><given-names>G</given-names></name><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group><article-title>From ancient medicine to modern medicine: ayurvedic concepts of health and their role in inflammation and cancer</article-title><source> J Soc Integr Oncol</source><year>2007</year><volume>5</volume><fpage>25</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">17309811</pub-id></element-citation></ref><ref id="B11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghorbani</surname><given-names>Z</given-names></name><name><surname>Hekmatdoost</surname><given-names>A</given-names></name><name><surname>Mirmiran</surname><given-names>P</given-names></name></person-group><article-title>Anti-hyperglycemic and insulin sensitizer effects of turmeric and its principle constituent curcumin</article-title><source> Int J Endocrinol Metab</source><year>2014</year><volume>12</volume><fpage>e18081</fpage><pub-id pub-id-type="pmid">25745485</pub-id></element-citation></ref><ref id="B12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>SC</given-names></name><name><surname>Patchva</surname><given-names>S</given-names></name><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group><article-title>Therapeutic roles of curcumin: lessons learned from clinical trials</article-title><source> AAPS J</source><year>2013</year><volume>15</volume><fpage>195</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">23143785</pub-id></element-citation></ref><ref id="B13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatcher</surname><given-names>H</given-names></name><name><surname>Planalp</surname><given-names>R</given-names></name><name><surname>Cho</surname><given-names>J</given-names></name><name><surname>Torti</surname><given-names>FM</given-names></name><name><surname>Torti</surname><given-names>SV</given-names></name></person-group><article-title>Curcumin: from ancient medicine to current clinical trials</article-title><source> Cell Mol Life Sci</source><year>2008</year><volume>65</volume><fpage>1631</fpage><lpage>1652</lpage><pub-id pub-id-type="pmid">18324353</pub-id></element-citation></ref><ref id="B14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howles</surname><given-names>PN</given-names></name></person-group><article-title>Cholesterol absorption and metabolism</article-title><source> Methods Mol Biol</source><year>2010</year><volume>602</volume><fpage>157</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">20012398</pub-id></element-citation></ref><ref id="B15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name></person-group><article-title>Clinical studies with curcumin</article-title><source> Adv Exp Med Biol</source><year>2007</year><volume>595</volume><fpage>471</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">17569225</pub-id></element-citation></ref><ref id="B16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kakarala</surname><given-names>M</given-names></name><name><surname>Brenner</surname><given-names>DE</given-names></name><name><surname>Korkaya</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Tazi</surname><given-names>K</given-names></name><name><surname>Ginestier</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Dontu</surname><given-names>G</given-names></name><name><surname>Wicha</surname><given-names>MS</given-names></name></person-group><article-title>Targeting breast stem cells with the cancer preventive compounds curcumin and piperine</article-title><source> Breast Cancer Res Treat</source><year>2010</year><volume>122</volume><fpage>777</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">19898931</pub-id></element-citation></ref><ref id="B17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name></person-group><article-title>Curcumin suppresses expression of low-density lipoprotein (LDL) receptor, leading to the inhibition of LDL-induced activation of hepatic stellate cells</article-title><source> Br J Pharmacol</source><year>2009</year><volume>157</volume><fpage>1354</fpage><lpage>1367</lpage><pub-id pub-id-type="pmid">19594758</pub-id></element-citation></ref><ref id="B18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazemi-Bajestani</surname><given-names>SM</given-names></name><name><surname>Ghayour-Mobarhan</surname><given-names>M</given-names></name><name><surname>Ebrahimi</surname><given-names>M</given-names></name><name><surname>Moohebati</surname><given-names>M</given-names></name><name><surname>Esmaeili</surname><given-names>HA</given-names></name><name><surname>Ferns</surname><given-names>GA</given-names></name></person-group><article-title>C-reactive protein associated with coronary artery disease in Iranian patients with angiographically defined coronary artery disease</article-title><source> Clin Lab</source><year>2007</year><volume>53</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">17323825</pub-id></element-citation></ref><ref id="B19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larejani</surname><given-names>B</given-names></name><name><surname>Zahedi</surname><given-names>F</given-names></name></person-group><article-title>Epidemiology of diabetes mellitus in Iran</article-title><source> Ir J Diabetes Met</source><year>2001</year><volume>1</volume><fpage>1</fpage><lpage>8</lpage></element-citation></ref><ref id="B20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Lv</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name></person-group><article-title>Recent progress in studying curcumin and its nano-preparations for cancer therapy</article-title><source> Curr pharm des</source><year>2013</year><volume>19</volume><fpage>1974</fpage><lpage>1993</lpage><pub-id pub-id-type="pmid">23116308</pub-id></element-citation></ref><ref id="B21"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Menon</surname><given-names>VP</given-names></name><name><surname>Sudheer</surname><given-names>AR</given-names></name></person-group><source>Antioxidant and anti-inflammatory properties of curcumin. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease</source><year>2007</year><publisher-loc>Texas</publisher-loc><publisher-name>Springer</publisher-name><fpage>105</fpage><lpage>125</lpage></element-citation></ref><ref id="B22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nezhad</surname><given-names>MZ</given-names></name><name><surname>Ghanbari</surname><given-names>P</given-names></name><name><surname>Shahryari</surname><given-names>B</given-names></name><name><surname>Aghasadeghi</surname><given-names>K</given-names></name></person-group><article-title>C-Reactive Protein in Angiographically Documented Stable Coronary Disease</article-title><source> Ir Cardiovas Res J</source><year>2009</year><volume>3</volume><fpage>97</fpage><lpage>101</lpage></element-citation></ref><ref id="B23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadi</surname><given-names>A</given-names></name><name><surname>Sahebkar</surname><given-names>A</given-names></name><name><surname>Iranshahi</surname><given-names>M</given-names></name><name><surname>Amini</surname><given-names>M</given-names></name><name><surname>Khojasteh</surname><given-names>R</given-names></name><name><surname>Ghayour-Mobarhan</surname><given-names>M</given-names></name><name><surname>Ferns</surname><given-names>GA</given-names></name></person-group><article-title>Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial</article-title><source> Phytother Res</source><year>2013</year><volume>27</volume><fpage>374</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">22610853</pub-id></element-citation></ref><ref id="B24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muthenna</surname><given-names>P</given-names></name><name><surname>Suryanarayana</surname><given-names>P</given-names></name><name><surname>Gunda</surname><given-names>SK</given-names></name><name><surname>Petrash</surname><given-names>JM</given-names></name><name><surname>Reddy</surname><given-names>GB</given-names></name></person-group><article-title>"Inhibition of aldose reductase by dietary antioxidant curcumin: mechanism of inhibition, specificity and significance</article-title><source> FEBS Lett</source><year>2009</year><volume>583</volume><fpage>3637</fpage><lpage>3642</lpage><pub-id pub-id-type="pmid">19850041</pub-id></element-citation></ref><ref id="B25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Na</surname><given-names>LX</given-names></name><name><surname>Zhang</surname><given-names>YL</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>LY</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Kong</surname><given-names>T</given-names></name><name><surname>Sun</surname><given-names>CH</given-names></name></person-group><article-title>Curcumin improves insulin resistance in skeletal muscle of rats</article-title><source> Nutr Metab Cardiovasc Dis</source><year>2011</year><volume>217</volume><fpage>526</fpage><lpage>533</lpage><pub-id pub-id-type="pmid">20227862</pub-id></element-citation></ref><ref id="B26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>Meininger</surname><given-names>G</given-names></name><name><surname>Sheng</surname><given-names>D</given-names></name><name><surname>Terranella</surname><given-names>L</given-names></name><name><surname>Stein</surname><given-names>PP</given-names></name></person-group><collab>Sitagliptin Study 024 Group</collab><article-title>Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial</article-title><source> Diabetes Obes Metab</source><year>2007</year><volume>92</volume><fpage>194</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">17300595</pub-id></element-citation></ref><ref id="B27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neerati</surname><given-names>P</given-names></name><name><surname>Devde</surname><given-names>R</given-names></name><name><surname>Gangi</surname><given-names>AK</given-names></name></person-group><article-title>Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus</article-title><source> Phytother Res</source><year>2014</year><volume>28</volume><fpage>1796</fpage><lpage>1800</lpage><pub-id pub-id-type="pmid">25044423</pub-id></element-citation></ref><ref id="B28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiyama</surname><given-names>T</given-names></name><name><surname>Mae</surname><given-names>T</given-names></name><name><surname>Kishida</surname><given-names>H</given-names></name><name><surname>Tsukagawa</surname><given-names>M</given-names></name><name><surname>Mimaki</surname><given-names>Y</given-names></name><name><surname>Kuroda</surname><given-names>M</given-names></name><name><surname>Sashida</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Kawada</surname><given-names>T</given-names></name><name><surname>Nakagawa</surname><given-names>K</given-names></name><name><surname>Kitahara</surname><given-names>M</given-names></name></person-group><article-title>Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice</article-title><source> J Agric Food Chem</source><year>2005</year><volume>53</volume><fpage>959</fpage><lpage>963</lpage><pub-id pub-id-type="pmid">15713005</pub-id></element-citation></ref><ref id="B29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pekkanen</surname><given-names>J</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Qiao</surname><given-names>Q</given-names></name><name><surname>Jousilahti</surname><given-names>P</given-names></name><name><surname>Lindstr&#x000f6;m</surname><given-names>J</given-names></name><name><surname>Group</surname><given-names>DS</given-names></name></person-group><article-title>Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria The DECODE study group European Diabetes Epidemiology Group Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe</article-title><source> Lancet</source><year>1999</year><volume>354</volume><fpage>617</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">10466661</pub-id></element-citation></ref><ref id="B30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettitt</surname><given-names>DJ</given-names></name><name><surname>Talton</surname><given-names>J</given-names></name><name><surname>Dabelea</surname><given-names>D</given-names></name><name><surname>Divers</surname><given-names>J</given-names></name><name><surname>Imperatore</surname><given-names>G</given-names></name><name><surname>Lawrence</surname><given-names>JM</given-names></name><name><surname>Liese</surname><given-names>AD</given-names></name><name><surname>Linder</surname><given-names>B</given-names></name><name><surname>Mayer-Davis</surname><given-names>EJ</given-names></name><name><surname>Pihoker</surname><given-names>C</given-names></name><name><surname>Saydah</surname><given-names>SH</given-names></name><name><surname>Standiford</surname><given-names>DA</given-names></name><name><surname>Hamman</surname><given-names>RF</given-names></name></person-group><collab>SEARCH for Diabetes in Youth Study Group</collab><article-title>Prevalence of Diabetes in US Youth in 2009: The SEARCH for Diabetes in Youth Study</article-title><source> Diabetes care</source><year>2014</year><volume>37</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">24041677</pub-id></element-citation></ref><ref id="B31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahimi</surname><given-names>HR</given-names></name><name><surname>Jaafari</surname><given-names>MR</given-names></name><name><surname>Mohammadpour</surname><given-names>AH</given-names></name><name><surname>Abnous</surname><given-names>K</given-names></name><name><surname>Ghayour</surname><given-names>Mobarhan M</given-names></name><name><surname>Ramezanzadeh</surname><given-names>E</given-names></name><name><surname>Mousavi</surname><given-names>F</given-names></name><name><surname>Kazemi</surname><given-names>Oskuee R</given-names></name></person-group><article-title>Curcumin: Reintroduced Therapeutic Agent from Traditional Medicine for Alcoholic Liver Disease</article-title><source> Asia Pacific J Med Tox</source><year>2015</year><volume>4</volume><fpage>25</fpage><lpage>30</lpage></element-citation></ref><ref id="B32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahimi</surname><given-names>HR</given-names></name><name><surname>Kazemi</surname><given-names>Oskuee R</given-names></name></person-group><article-title>Curcumin From Traditional Iranian Medicine to Molecular Medicine</article-title><source> Razavi Int J Med</source><year>2014</year><volume>2</volume><fpage>3</fpage><lpage>4</lpage></element-citation></ref><ref id="B33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saini</surname><given-names>V</given-names></name></person-group><article-title>Molecular mechanisms of insulin resistance in type 2 diabetes mellitus</article-title><source> World J Diabetes</source><year>2010</year><volume>1</volume><fpage>68</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">21537430</pub-id></element-citation></ref><ref id="B34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandur</surname><given-names>SK</given-names></name><name><surname>Pandey</surname><given-names>MK</given-names></name><name><surname>Sung</surname><given-names>B</given-names></name><name><surname>Ahn</surname><given-names>KS</given-names></name><name><surname>Murakami</surname><given-names>A</given-names></name><name><surname>Sethi</surname><given-names>G</given-names></name><name><surname>Limtrakul</surname><given-names>P</given-names></name><name><surname>Badmaev</surname><given-names>V</given-names></name><name><surname>Aggarwal</surname><given-names>BB</given-names></name></person-group><article-title>Curcumin, demethoxycurcumin, bisdemethoxycurcumin,tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism</article-title><source> Carcinogenesis</source><year>(2007)</year><volume>28</volume><fpage>1765</fpage><lpage>1773</lpage><pub-id pub-id-type="pmid">17522064</pub-id></element-citation></ref><ref id="B35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santel</surname><given-names>T</given-names></name><name><surname>Pflug</surname><given-names>G</given-names></name><name><surname>Hemdan</surname><given-names>NY</given-names></name><name><surname>Sch&#x000e4;fer</surname><given-names>A</given-names></name><name><surname>Hollenbach</surname><given-names>M</given-names></name><name><surname>Buchold</surname><given-names>M</given-names></name><name><surname>Hintersdorf</surname><given-names>A</given-names></name><name><surname>Lindner</surname><given-names>I</given-names></name><name><surname>Otto</surname><given-names>A</given-names></name><name><surname>Bigl</surname><given-names>M</given-names></name><name><surname>Oerlecke</surname><given-names>I</given-names></name><name><surname>Hutschenreuther</surname><given-names>A</given-names></name><name><surname>Sack</surname><given-names>U</given-names></name><name><surname>Huse</surname><given-names>K</given-names></name><name><surname>Groth</surname><given-names>M</given-names></name><name><surname>Birkemeyer</surname><given-names>C</given-names></name><name><surname>Schellenberger</surname><given-names>W</given-names></name><name><surname>Gebhardt</surname><given-names>R</given-names></name><name><surname>Platzer</surname><given-names>M</given-names></name><name><surname>Weiss</surname><given-names>T</given-names></name><name><surname>Vijayalakshmi</surname><given-names>MA</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>M</given-names></name><name><surname>Birkenmeier</surname><given-names>G</given-names></name></person-group><article-title>Curcumin inhibits glyoxalase 1&#x02014;a possible link to its anti-inflammatory and anti-tumor activity</article-title><source> PLoS One</source><year>2008</year><volume>3</volume><fpage>e3508</fpage><pub-id pub-id-type="pmid">18946510</pub-id></element-citation></ref><ref id="B36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Kulkarni</surname><given-names>SK</given-names></name><name><surname>Chopra</surname><given-names>K</given-names></name></person-group><article-title>Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats</article-title><source> Clin Exp Pharmacol Physiol</source><year>2006</year><volume>33</volume><fpage>940</fpage><lpage>945</lpage><pub-id pub-id-type="pmid">17002671</pub-id></element-citation></ref><ref id="B37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singer</surname><given-names>DE</given-names></name><name><surname>Nathan</surname><given-names>DM</given-names></name><name><surname>Anderson</surname><given-names>KM</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>Evans</surname><given-names>JC</given-names></name></person-group><article-title>Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study</article-title><source> Diabetes</source><year>1992</year><volume>41</volume><fpage>202</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">1733810</pub-id></element-citation></ref><ref id="B38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smithson</surname><given-names>KW</given-names></name><name><surname>Millar</surname><given-names>DB</given-names></name><name><surname>Jacobs</surname><given-names>LR</given-names></name><name><surname>Gray</surname><given-names>GM</given-names></name></person-group><article-title>Intestinal diffusion barrier: unstirred water layer or membrane surface mucous coat?</article-title><source> Science</source><year>1981</year><volume>214</volume><fpage>1241</fpage><lpage>1244</lpage><pub-id pub-id-type="pmid">7302593</pub-id></element-citation></ref><ref id="B39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soni</surname><given-names>K</given-names></name><name><surname>Kuttan</surname><given-names>R</given-names></name></person-group><article-title>Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers</article-title><source> Indian J Physio Pharmacol</source><year>1992</year><volume>36</volume><fpage>273</fpage><lpage>273</lpage></element-citation></ref><ref id="B40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thamake</surname><given-names>SI</given-names></name><name><surname>Raut</surname><given-names>SL</given-names></name><name><surname>Ranjan</surname><given-names>AP</given-names></name><name><surname>Gryczynski</surname><given-names>Z</given-names></name><name><surname>Vishwanatha</surname><given-names>JK</given-names></name></person-group><article-title>Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy</article-title><source> Nanotechnology</source><year>2011</year><volume>22</volume><fpage>035101</fpage><pub-id pub-id-type="pmid">21149963</pub-id></element-citation></ref><ref id="B41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatesha</surname><given-names>SH</given-names></name><name><surname>Berman</surname><given-names>BM</given-names></name><name><surname>Moudgil</surname><given-names>KD</given-names></name></person-group><article-title>Herbal medicinal products target defined biochemical and molecular mediators of inflammatory autoimmune arthritis</article-title><source> Bioorg med chem</source><year>2011</year><volume>19</volume><fpage>21</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">21115252</pub-id></element-citation></ref><ref id="B42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisberg</surname><given-names>SP</given-names></name><name><surname>Leibel</surname><given-names>R</given-names></name><name><surname>Tortoriello</surname><given-names>DV</given-names></name></person-group><article-title>Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity</article-title><source> Endocrinology</source><year>2008</year><volume>149</volume><fpage>3549</fpage><lpage>3558</lpage><pub-id pub-id-type="pmid">18403477</pub-id></element-citation></ref><ref id="B43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wild</surname><given-names>S</given-names></name><name><surname>Roglic</surname><given-names>G</given-names></name><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Sicree</surname><given-names>R</given-names></name><name><surname>King</surname><given-names>H</given-names></name></person-group><article-title>Global prevalence of diabetes estimates for the year 2000 and projections for 2030</article-title><source> Diabetes care</source><year>2004</year><volume>27</volume><fpage>1047</fpage><lpage>1053</lpage><pub-id pub-id-type="pmid">15111519</pub-id></element-citation></ref><ref id="B44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>GY</given-names></name><name><surname>Eisenberg</surname><given-names>DM</given-names></name><name><surname>Kaptchuk</surname><given-names>TJ</given-names></name><name><surname>Phillips</surname><given-names>RS</given-names></name></person-group><article-title>Systematic review of herbs and dietary supplements for glycemic control in diabetes</article-title><source> Diabetes Care</source><year>2003</year><volume>26</volume><fpage>1277</fpage><lpage>1294</lpage><pub-id pub-id-type="pmid">12663610</pub-id></element-citation></ref></ref-list></back></article>